First-line therapy for renal cell carcinoma has primarily been tyrosine kinase inhibitors that target vascular endothelial growth factor and other receptors.
MDedge News
First-line therapy for renal cell carcinoma has primarily been tyrosine kinase inhibitors that target vascular endothelial growth factor and other receptors.
MDedge News
